NextCure Provides Updates on NC318 Clinical Program

Posted: December 17, 2020 at 7:55 am

BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target.

Excerpt from:
NextCure Provides Updates on NC318 Clinical Program

Related Posts